Radiation Oncology/Epidemiology/Survival

Cancer Survival Data Disease Median OS 1-year OS 2-year OS 5-year OS 10-year OS Chordoma     Overall (SEER data) 6.3 years     68% 40% Glioma   Low Grade (WHO II)     RT alone (EORTC 22844) ~6 years     59%       RT alone (NCCTG) ~9 years   94% 72%       Observation (EORTC 22845) 7.4 years     66%     High Grade (WHO III)     RT alone (RTOG 9402) 4.7 years     46%       RT alone (EORTC 26951) 3.4 years     37%     High Grade (WHO IV)     Observation (BTCG 69-01) 3.2 months             RT alone (BTCG 69-01) 8.1 months         Pancreas   Resectable     Surgery only (CONKO-001) 1.7 years     9%       Adjuvant 5FU/RT (GITSG 9173) 1.7 years   42%         Adjuvant 5FU/RT/Chemo (ESPAC-1) 1.7 years             Adjuvant GEM-RT/5-FU/GEM (RTOG 9704) 1.7 years             Adjuvant GEM (CONKO-001) 1.9 years     21%     Unresectable     No treatment ~4 months             Palliative bypass 6-7 months             RT/5-FU (FFCD-SFRO) 9 months 32%           RT/GEM (ECOG E4201) 11 months             GEM (FFCD-SFRO) 13 months 53%           RT/GEM (Taipei) 14 months 56% 15%         RT/TNFerade(PACT) 1.4 years 71%       Prostate   Early Stage (cT1-T2)     Watchful waiting (SPCG-4)         86%     Surgery (SPCG-4)         91% NSCLC   Early Stage Operable     Surgery (Stage I) composite       65%       Surgery (Stage I) Brazil       95%       Conventional RT (Stage I) composite       20%       SBRT (Stage I) Japan       83%       Surgery (Stage II)       45%   Spinal Cord Compression     RT Alone (Patchell) 3 months     Surgery + RT (Patchell) 4 months